SCH900182

SCH900182 is a preclinical **small-molecule phosphodiesterase 4 inhibitor** developed by **Schering-Plough** and later associated with **Merck** after acquisition. It was investigated as an **inhaled anti-inflammatory respiratory candidate** for diseases such as **chronic obstructive pulmonary disease** and **asthma**. By inhibiting PDE4, SCH900182 is intended to raise intracellular cyclic AMP levels in inflammatory cells and airway tissues, thereby suppressing inflammatory signaling and potentially promoting bronchodilation. Publicly available review literature describes SCH900182 as a highly potent PDE4 inhibitor with reported preclinical efficacy in multiple species, but it does **not appear to have advanced beyond preclinical development** and no marketed product or assigned INN could be verified from the available public sources.